Q4 EPS Estimate for Rigel Pharmaceuticals Lowered by Analyst

Key Points

• HC Wainwright cut its Q4 2026 EPS forecast for Rigel Pharmaceuticals to $0.87 from $0.94, while maintaining a Buy rating and an $85 price target.
• Rigel reported quarterly EPS of $0.65, below analysts’ $0.92 consensus, though revenue of $80.89 million topped expectations of $80.10 million. Newly launched VEPPANU contributed $6.6 million in initial sales.
• Analyst views are mixed: the stock has a consensus Hold rating and an average price target of $65.50, with three Buy, two Hold, and one Sell rating.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Equities research analysts at HC Wainwright decreased their Q4 2026 EPS estimates for Rigel Pharmaceuticals in a research note issued on Friday, November 6th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of $0.87 per share for the quarter, down from their previous forecast of $0.94. HC Wainwright has a "Buy" rating and a $85.00 price objective on the stock. The consensus estimate for Rigel Pharmaceuticals' current full-year earnings is $2.98 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals' FY2027 earnings at $4.78 EPS.

Other equities research analysts have also issued research reports about the company. Weiss Ratings upgraded Rigel Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 8th. Piper Sandler restated a "neutral" rating and issued a $49.00 price objective (up from $40.00) on shares of Rigel Pharmaceuticals in a research report on Monday, August 17th. Citigroup reaffirmed a "buy" rating on shares of Rigel Pharmaceuticals in a research note on Thursday, August 6th. Cantor Fitzgerald increased their target price on Rigel Pharmaceuticals from $43.00 to $47.00 and gave the stock a "neutral" rating in a research report on Friday. Finally, Zacks Research downgraded Rigel Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Wednesday, October 14th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Rigel Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $65.50.

Rigel Pharmaceuticals Stock Performance

RIGL opened at $39.65 on Monday. The stock has a market cap of $733.52 million, a price-to-earnings ratio of 2.56 and a beta of 1.28. The firm's fifty day moving average is $47.79 and its 200 day moving average is $37.47. Rigel Pharmaceuticals has a fifty-two week low of $24.95 and a fifty-two week high of $52.60.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $0.65 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.27). The firm had revenue of $80.89 million during the quarter, compared to analysts' expectations of $80.10 million. Rigel Pharmaceuticals had a return on equity of 15.25% and a net margin of 106.59%.

Hedge Funds Weigh In On Rigel Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Jupiter Topco LLC purchased a new stake in Rigel Pharmaceuticals in the 2nd quarter worth $3,450,000. Empowered Funds LLC purchased a new position in shares of Rigel Pharmaceuticals during the first quarter valued at about $2,234,000. Bank of America Corp DE purchased a new position in shares of Rigel Pharmaceuticals during the second quarter valued at about $4,832,000. Bank of New York Mellon Corp purchased a new position in shares of Rigel Pharmaceuticals during the second quarter valued at about $4,233,000. Finally, Man Group plc purchased a new position in shares of Rigel Pharmaceuticals during the second quarter valued at about $814,000. 66.23% of the stock is owned by hedge funds and other institutional investors.

Rigel Pharmaceuticals News Roundup

Here are the key news stories impacting Rigel Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue was $80.9 million, just above the $80.1 million expected, and Rigel reported $13.2 million in net income. Newly launched VEPPANU generated $6.6 million in initial sales after becoming commercially available in mid-August. Rigel Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: Cantor Fitzgerald lifted its price target to $47 from $43, while maintaining a neutral rating. Cantor Fitzgerald price target
• Negative Sentiment: Adjusted earnings were $0.65 per share, missing analyst estimates of roughly $0.87–$0.92 and falling from $1.46 a year earlier. The earnings shortfall is the clearest near-term negative for the stock. Rigel Pharmaceuticals misses Q3 earnings estimates

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc NASDAQ: RIGL is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel's primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.